Bevacizumab (Avastin): An anti-angiogenic drug associated with osteonecrosis of the jaw.
Department of Oral Craniofacial Biological Sciences, Dental School, University of Maryland, Baltimore, USA.
Richard L
RL
Wynn
D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects; D000068258:Bevacizumab; D059266:Bisphosphonate-Associated Osteonecrosis of the Jaw / Q000209:etiology; D002986:Clinical Trials as Topic; D017742:Dental Care for Chronically Ill; D004164:Diphosphonates / Q000009:adverse effects; D004357:Drug Synergism; D006801:Humans; D007571:Jaw Diseases / Q000139:chemically induced*; D010020:Osteonecrosis / Q000139:chemically induced; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D004164:Diphosphonates; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab